This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients accrued
Patients with multiple myeloma
Number of approved sites
M1000 Biobank participants
Monday 19 October, 7.00am NZDT, Weta Uncorked, Auckland, New Zealand
Read moreMRDR report for belantamab mafodotin submitted to Pharmaceutical Benefits Advisory Committee (PBAC) public call.
Read moreMyeloma Australia Medical and Scientific Advisory Group (MSAG) Meeting - 1-2 May 2026
Read moreThe MRDR has now surpassed an exciting milestone of over 9,000 registered patients.
Read more
